<DOC>
	<DOCNO>NCT01587222</DOCNO>
	<brief_summary>The aim study evaluate treatment midodrine , octreotide albumin 12 week patient hepatorenal syndrome . Fifteen patient enrol follow 16 week . The effect renal function evaluate 12 16 week begin treatment isotopic evidence biochemist determination . Also evaluate arterial pressure determination vasoactive hormone ( plasma renin , aldosterone norepinephrine ) .</brief_summary>
	<brief_title>Midodrine , Octreotide Albumin : Impact Renal Function Patients With Liver Cirrhosis Renal Failure</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hepatorenal Syndrome</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Midodrine</mesh_term>
	<criteria>Age 18 80 year Cirrhosis liver define clinical , biochemical histological Functional renal failure serum creatinine great 1.2 mg / dl le 2.5 mg / dl . That , properly inform , give consent participate study undergo test examination entail Women childbearing potential : pregnancy test negative serum urine , acceptance use adequate contraception since least 14 day prior first dose study drug 14 day last dose Pregnant woman , nurse mother , intend become pregnant study period Systolic blood pressure ≥ 150 mmHg / diastolic blood pressure ≥ 90 mmHg Previous treatment transjugular intrahepatic portosystemic shunt ( TIPS ) surgical portosystemic shunt Use antibiotic seven day prior inclusion study except prophylactic ( ie . prophylaxis spontaneous bacterial peritonitis ) Cardiac respiratory failure Positive human immunodeficiency virus Urinary retention Ischemic heart disease peripheral vascular disease . Narrow Angle Glaucoma Cerebrovascular occlusion Aortic Aneurysm Thyrotoxicosis Pheochromocytoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>